Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

F. Seymour, John; J. Kipps, Thomas; F. Eichhorst, Barbara; D’Rozario, James; J. Owen, Carolyn; Assouline, Sarit; Lamanna, Nicole; Robak, Tadeusz; de la Serna, Javier; Jaeger, Ulrich; Cartron, Guillaume; Montillo, Marco; Mellink, Clemens; Chyla, Brenda; Panchal, Anesh; Lu, Tong; Q. Wu, Jenny; Jiang, Yanwen; Lefebure, Marcus; Boyer, Michelle; P. Kater, Arnon

doi:10.1182/blood.2021015014

Public

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Shared by NobleBlocks on Aug 25, 2022 • 12:00 AM UTC

Authors:

John F. Seymour

Thomas J. Kipps

Barbara F. Eichhorst

Abstract

Abstract The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (P...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!